First Medicine disclosed an earnings forecast, expecting attributable net profit for the first half of 2026 to be between 23 million yuan and 28 million yuan, a year-on-year increase of 64% to 99.65%. Deducted non-recurring net profit is expected to be between 1.05 million yuan and 1.55 million yuan, a year-on-year decline of 82.8% to 88.35%. The rise in attributable net profit is mainly due to a wholly-owned subsidiary receiving housing expropriation compensation, while the decline in deducted non-recurring net profit is affected by intensified competition in the pharmaceutical distribution industry and new stores still being in the performance growth phase.
Shanghai No1 Pharmacy Co LtdAttributable net profit expected to rise 64%-99.65% due to housing expropriation compensation.